CTMX - CytomX Therapeutics, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Currency in USD

Valuation measures4

Market cap (intra-day) 116.76M
Enterprise value -58.84M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.25
Price/book (mrq)5.04
Enterprise value/revenue -0.87
Enterprise value/EBITDA 0.81

Trading information

Stock price history

Beta (5Y monthly) 0.65
52-week change 38.07%
S&P500 52-week change 31.77%
52-week high 33.0200
52-week low 31.1700
50-day moving average 31.6897
200-day moving average 31.7787

Share statistics

Avg vol (3-month) 3755.05k
Avg vol (10-day) 3447.38k
Shares outstanding 566.34M
Implied shares outstanding 6N/A
Float 853.16M
% held by insiders 11.47%
% held by institutions 157.42%
Shares short (14 May 2023) 42.13M
Short ratio (14 May 2023) 44.66
Short % of float (14 May 2023) 43.23%
Short % of shares outstanding (14 May 2023) 43.21%
Shares short (prior month 13 Apr 2023) 42.25M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)30 Mar 2023


Profit margin -104.47%
Operating margin (ttm)-99.41%

Management effectiveness

Return on assets (ttm)-15.81%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)67.62M
Revenue per share (ttm)1.02
Quarterly revenue growth (yoy)159.90%
Gross profit (ttm)53.16M
EBITDA -64.79M
Net income avi to common (ttm)-70.65M
Diluted EPS (ttm)-1.0300
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)204.5M
Total cash per share (mrq)3.08
Total debt (mrq)17.08M
Total debt/equity (mrq)N/A
Current ratio (mrq)1.40
Book value per share (mrq)-1.31

Cash flow statement

Operating cash flow (ttm)-60.13M
Levered free cash flow (ttm)17.69M